Study of Motor Inhibition in Parkinson's Disease and Focal Hand Dystonia (PD-INHIB)
Parkinson Disease
About this trial
This is an interventional diagnostic trial for Parkinson Disease focused on measuring Parkinson Disease
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of idiopathic PD (according to the United Kingdom PD Society Brain Bank Clinical Diagnostic Criteria) (for PD participants)
- Good response to levodopa (improvement on the UPDRS-III scale) (for PD participants)
- Hoehn and Yahr stage: < or = 3 (for PD participants)
- Absence of severe tremor (for PD participants)
- Absence of dyskinesia (for PD participants)
- Between 18 and 85 years old (for all participants)
- Normal or corrected-to-normal vision (for all participants)
Exclusion Criteria (for all participants):
- Severe cognitive impairment (Score of <21/30 with the Montreal Cognitive Assessment (MoCA))
- MRI-incompatible metal device in the body
- History of major psychiatric or neurological disorder (other than PD for the patient group)
- Personal or family history of epilepsy
- History of substance use disorder (except nicotine)
- Untreated or unstable medical conditions that could interfere with cognitive functioning
- Undergoing any drug treatment that can significantly alter task performance or neural activity
Sites / Locations
- Cliniques universitaires Saint-LucRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Parkinson's disease (PD) patients Group 1
Parkinson's disease (PD) patients Group 2
Healthy individuals
PD patients treated by Dopamine replacement therapy, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
PD patients treated by Deep Brain Stimulation, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
Healthy participants, aged between 18 and 85, will be recruited as control subjects by means of ads posting.